Tizaro5 mg/0.5 ml

Established / FDA-Approved Uses

• Type 2 diabetes mellitus: Tizaro 5 mg/0.5 ml is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.
• Chronic weight management: Tizaro 5 mg/0.5 ml is indicated, in combination with a reduced-calorie diet and increased physical activity, for chronic weight management in adults with obesity (BMI ≥30 kg/m²), or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbid condition (e.g., hypertension, dyslipidaemia, type 2 diabetes, or cardiovascular disease).
• Moderate-to-severe obstructive sleep apnea (OSA): Tizaro 5 mg/0.5 ml is indicated, together with a reduced-calorie diet and increased physical activity, to treat moderate-to-severe OSA in adults with obesity.

Important Notes on Use

• Tizaro 5 mg/0.5 ml is not indicated for type 1 diabetes mellitus.
• Tizaro 5 mg/0.5 ml should not be combined with other Tizaro 5 mg/0.5 ml-containing products or any other GLP-1 receptor agonist.
• Use of Tizaro 5 mg/0.5 ml for weight loss purely for cosmetic reasons without a qualifying comorbidity or BMI criterion is not an approved indication.

Tizaro 5 mg/0.5 ml is a novel, first-in-class injectable medicine that acts as a dual agonist at both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. By activating both incretin pathways, Tizaro 5 mg/0.5 ml improves blood glucose control in people with type 2 diabetes and produces substantial, sustained weight loss when combined with lifestyle changes. It is administered as a once-weekly subcutaneous injection and is used long-term under medical supervision, with the dose gradually increased (titrated) over several weeks to improve tolerability.

Tizaro 5 mg/0.5 ml belongs to the Dual GIP/GLP-1 Receptor Agonist (Incretin Mimetic) class; it is used as an Antidiabetic and Anti-obesity Agent.

Tizaro 5 mg/0.5 ml is a synthetic peptide that acts as an agonist at both the GIP receptor and the GLP-1 receptor, the two primary incretin hormone receptors. By activating these receptors, Tizaro 5 mg/0.5 ml:

• Increases glucose-dependent insulin secretion from pancreatic beta cells.
• Reduces glucagon secretion in a glucose-dependent manner, lowering hepatic glucose output.
• Slows gastric emptying, which contributes to increased satiety and reduced food intake.
• Acts on appetite-regulating centres in the brain to reduce hunger and caloric intake, leading to significant weight loss.

The combined GIP/GLP-1 agonism of Tizaro 5 mg/0.5 ml produces greater improvements in glycaemic control and body weight than selective GLP-1 receptor agonists alone in clinical trials. Tizaro 5 mg/0.5 ml has an elimination half-life of approximately 5 days, supporting once-weekly dosing, and is metabolised via proteolytic cleavage, beta-oxidation of the fatty acid side chain, and amide hydrolysis, with elimination primarily through excretion of metabolites.

For subcutaneous injection only, into the abdomen, thigh, or upper arm, once weekly on the same day each week; rotate injection sites; may be taken with or without food; not for intravenous or intramuscular use.

Clinically Significant Interactions

• Insulin and insulin secretagogues (e.g., sulfonylureas): Concomitant use with Tizaro 5 mg/0.5 ml increases the risk of hypoglycemia; a dose reduction of the insulin or secretagogue may be needed, with increased blood glucose self-monitoring.
• Oral medications with narrow therapeutic index (e.g., warfarin): Tizaro 5 mg/0.5 ml delays gastric emptying, which can alter the rate and extent of absorption of co-administered oral drugs; monitor closely when starting or titrating Tizaro 5 mg/0.5 ml.
• Oral hormonal contraceptives: Delayed gastric emptying from Tizaro 5 mg/0.5 ml may reduce contraceptive efficacy; advise use of a non-oral contraceptive method, or add a barrier method for 4 weeks after starting Tizaro 5 mg/0.5 ml and for 4 weeks after each dose increase.
• Alcohol: May increase the risk of hypoglycemia or gastrointestinal side effects when combined with Tizaro 5 mg/0.5 ml; use cautiously.

Always inform the prescriber of all other medicines, supplements, and herbal products being used before starting Tizaro 5 mg/0.5 ml.

Very Common / Common

• Nausea (most common, especially during dose escalation)
• Diarrhea
• Decreased appetite
• Vomiting
• Constipation
• Dyspepsia (indigestion)
• Abdominal pain
• Injection site reactions (redness, itching, swelling)
• Fatigue
• Belching, flatulence

Less Common but Serious

• Acute pancreatitis
• Hypoglycemia (particularly when combined with insulin or sulfonylureas)
• Gallbladder disease, including cholelithiasis (gallstones) and cholecystitis
• Acute kidney injury (usually secondary to dehydration from severe GI effects)
• Hypersensitivity reactions, including anaphylaxis and angioedema
• Worsening of diabetic retinopathy complications in patients with pre-existing retinopathy on insulin

Most gastrointestinal side effects of Tizaro 5 mg/0.5 ml are dose-related, occur mainly during dose escalation, and tend to diminish over time. Patients should seek prompt medical attention for severe or persistent abdominal pain, signs of an allergic reaction, or symptoms of low blood sugar.

Pregnancy

Tizaro 5 mg/0.5 ml is not recommended during pregnancy. Animal studies have shown adverse effects on fetal growth associated with Tizaro 5 mg/0.5 ml-induced maternal weight loss and reduced food intake; human data are limited. Because of the substantial weight loss it causes, Tizaro 5 mg/0.5 ml may not be appropriate during pregnancy regardless of prior indication. Patients who become pregnant should discontinue Tizaro 5 mg/0.5 ml and consult their physician promptly; use only if a physician determines that no suitable alternative exists and potential benefit clearly justifies potential risk to the fetus.

Lactation

There are limited data on the presence of Tizaro 5 mg/0.5 ml in human milk or its effects on the breastfed infant or on milk production. As a large peptide molecule, Tizaro 5 mg/0.5 ml is expected to be present in breast milk at low levels, and oral infant absorption is expected to be minimal. Breastfeeding mothers should discuss the use of Tizaro 5 mg/0.5 ml with their physician, weighing the mother's clinical need for the medicine against any potential risk to the infant.

Boxed Warning: Risk of Thyroid C-Cell Tumors

In rodent studies, Tizaro 5 mg/0.5 ml caused dose-dependent and treatment-duration-dependent thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). Whether Tizaro 5 mg/0.5 ml causes MTC in humans is unknown, as human relevance has not been determined. Tizaro 5 mg/0.5 ml is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2 (see Contraindications). Patients should be counselled on the symptoms of thyroid tumors (a lump or swelling in the neck, hoarseness, difficulty swallowing, or shortness of breath) and instructed to report these promptly.

Other Key Precautions

• Pancreatitis: Discontinue Tizaro 5 mg/0.5 ml promptly if pancreatitis is suspected (severe, persistent abdominal pain, with or without vomiting) and do not restart if confirmed.
• Hypoglycemia: Risk is increased when Tizaro 5 mg/0.5 ml is used with insulin or sulfonylureas (see Interactions); monitor blood glucose closely.
• Gallbladder disease: Monitor for signs of cholelithiasis or cholecystitis (right upper abdominal pain, fever, jaundice).
• Acute kidney injury: Gastrointestinal adverse reactions (nausea, vomiting, diarrhea) can cause dehydration, which may worsen renal function, particularly in patients with pre-existing renal impairment; ensure adequate hydration.
• Diabetic retinopathy: Patients with a history of diabetic retinopathy who are also on insulin should be monitored for progression while using Tizaro 5 mg/0.5 ml.
• Severe gastrointestinal disease: Not recommended in patients with severe gastroparesis due to the drug's effect of slowing gastric emptying.
• Hypersensitivity reactions: Discontinue Tizaro 5 mg/0.5 ml immediately if a serious hypersensitivity reaction occurs and seek prompt medical care.
• Pre-operative use: Because Tizaro 5 mg/0.5 ml delays gastric emptying, inform the surgical/anesthesia team before any procedure requiring sedation or general anesthesia, as there may be an increased risk of pulmonary aspiration.
• Injection device use: Pens/devices must never be shared between patients, even with a new needle, due to the risk of transmitting infection.
• Use with caution in patients with a history of suicidal ideation or mood changes; report any new or worsening depression or suicidal thoughts to a physician promptly.

Overdose of Tizaro 5 mg/0.5 ml may increase the frequency and severity of gastrointestinal adverse reactions (severe nausea, vomiting, diarrhea) and may increase the risk of hypoglycemia, particularly if used with insulin or insulin secretagogues. There is no specific antidote for Tizaro 5 mg/0.5 ml overdose. In case of a suspected overdose, seek immediate medical attention or contact a poison control center/emergency services right away. Management is supportive, taking into account the long (approximately 5-day) elimination half-life of Tizaro 5 mg/0.5 ml, and may include monitoring for dehydration, electrolyte disturbances, and blood glucose levels as advised by a physician.

Pediatric Use

Tizaro 5 mg/0.5 ml is approved for improving glycemic control in type 2 diabetes in pediatric patients 10 years of age and older, using the same dosing and titration schedule as adults, up to a maximum of 15 mg weekly. The safety and efficacy of Tizaro 5 mg/0.5 ml for chronic weight management or obstructive sleep apnea have not been established in patients under 18 years of age.

Elderly (Geriatric) Use

No significant differences in safety or efficacy of Tizaro 5 mg/0.5 ml have been observed between elderly patients (65 years and older) and younger adults; no dose adjustment is required based on age alone, though elderly patients may be more susceptible to dehydration-related complications.

Renal Impairment

No dose adjustment of Tizaro 5 mg/0.5 ml is required for mild-to-severe renal impairment; however, patients with renal impairment should be monitored for dehydration if gastrointestinal side effects occur.

Hepatic Impairment

No dose adjustment of Tizaro 5 mg/0.5 ml is required in patients with hepatic impairment.

Incretin Mimetic; Dual GIP/GLP-1 Receptor Agonist; Antidiabetic Agent; Anti-obesity Agent